Recurrent Ovarian Cancer - Sculpting a Promising Future with Surgery
- PMID: 34874635
- DOI: 10.1056/NEJMe2116353
Recurrent Ovarian Cancer - Sculpting a Promising Future with Surgery
Comment on
-
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.N Engl J Med. 2021 Dec 2;385(23):2123-2131. doi: 10.1056/NEJMoa2103294. N Engl J Med. 2021. PMID: 34874631 Clinical Trial.
Similar articles
-
[Ⅲ.Surgery for Platinum Sensitive Recurrent Epithelial Ovarian Cancer].Gan To Kagaku Ryoho. 2019 Feb;46(2):240-243. Gan To Kagaku Ryoho. 2019. PMID: 30914526 Japanese. No abstract available.
-
Should secondary cytoreduction be used in recurrent ovarian cancer?Clin Adv Hematol Oncol. 2022 Apr;20(4):215-217. Clin Adv Hematol Oncol. 2022. PMID: 35389385 No abstract available.
-
Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study.BMC Cancer. 2014 Jan 14;14:22. doi: 10.1186/1471-2407-14-22. BMC Cancer. 2014. PMID: 24422892 Free PMC article. Clinical Trial.
-
Surgical management of recurrent ovarian cancer.Gynecol Oncol. 2016 Aug;142(2):357-67. doi: 10.1016/j.ygyno.2016.04.537. Epub 2016 May 10. Gynecol Oncol. 2016. PMID: 27130407 Review.
-
The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse.Updates Surg. 2014 Jun;66(2):109-13. doi: 10.1007/s13304-013-0229-9. Epub 2013 Aug 27. Updates Surg. 2014. PMID: 23980020 Review.
Cited by
-
Immunostimulatory gene therapy combined with checkpoint blockade reshapes tumor microenvironment and enhances ovarian cancer immunotherapy.Acta Pharm Sin B. 2024 Feb;14(2):854-868. doi: 10.1016/j.apsb.2023.08.014. Epub 2023 Aug 19. Acta Pharm Sin B. 2024. PMID: 38322330 Free PMC article.
-
Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial.Nat Med. 2024 Aug;30(8):2181-2188. doi: 10.1038/s41591-024-02981-0. Epub 2024 Jun 1. Nat Med. 2024. PMID: 38824243 Clinical Trial.
-
Immunostimulatory CKb11 gene combined with immune checkpoint PD-1/PD-L1 blockade activates immune response and simultaneously overcomes the immunosuppression of cancer.Bioact Mater. 2024 May 23;39:239-254. doi: 10.1016/j.bioactmat.2024.05.014. eCollection 2024 Sep. Bioact Mater. 2024. PMID: 38832303 Free PMC article.
-
Ferroptosis, necroptosis, and pyroptosis in the occurrence and development of ovarian cancer.Front Immunol. 2022 Jul 25;13:920059. doi: 10.3389/fimmu.2022.920059. eCollection 2022. Front Immunol. 2022. PMID: 35958626 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical